NET ASSET VALUE – 30 April 2025
On the 30 April 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,965 million and NAV per share was SEK 50.79.
|
Allocation of NAV |
Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 452 | 5.80 | 11.4% |
| Xspray Pharma | 18% | 231 | 2.96 | 5.8% |
| Empros Pharma | 79% | 204 | 2.62 | 5.2% |
| KAHR Medical | 31% | 182 | 2.33 | 4.6% |
| Lipum | 57% | 182 | 2.33 | 4.6% |
| Atrogi | 37% | 176 | 2.25 | 4.4% |
| Xintela | 61% | 165 | 2.11 | 4.1% |
| Microbiotica | 10% | 129 | 1.65 | 3.2% |
| Geneos Therapeutics | 12% | 93 | 1.19 | 2.3% |
| AnaCardio | 14% | 69 | 0.89 | 1.7% |
| Mendus | 24% | 60 | 0.77 | 1.5% |
| Toleranzia | 53% | 60 | 0.77 | 1.5% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.70 | 1.4% |
| Synerkine Pharma | 43% | 54 | 0.70 | 1.4% |
| Vitara Biomedical | 11% | 48 | 0.62 | 1.2% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.40 | 0.8% |
| Sixera Pharma | 24% | 27 | 0.35 | 0.7% |
| Egetis Therapeutics | 2% | 22 | 0.28 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,277 | 29.17 | 57.4% | |
| Commercial Growth | ||||
| Symcel | 30% | 192 | 2.46 | 4.8% |
| NorthX Biologics | 92% | 189 | 2.42 | 4.8% |
| Chromafora | 30% | 73 | 0.93 | 1.8% |
| Nanologica | 43% | 47 | 0.61 | 1.2% |
| Frontier Biosolutions | 2% | 18 | 0.23 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 536 | 6.87 | 13.5% | |
| Limited Partnerships, total | 90 | 1.15 | 2.3% | |
| Assets related to Portfolio companies | 266 | 3.41 | 6.7% | |
| Other assets and liabilities | 795 | 10.18 | 20.0% | |
| Net asset value | 3,965 | 50.79 | 100.0% | |